In this webinar, you will learn:
- Six frequently missed observations with critical impacts on antibody validation, hit selection and candidate characterization efforts.
- Antibody biochemistry tips for design of SPR, and mass spectrometry-based epitope mapping workflows.
Characterizing Antibody Epitopes: What the Experts Say You’re Missing
In this webinar, we review 6 frequently missed observations in early pre-clinical antibody development that translate to failed antibody candidates in later stages. Our insights here are derived from hundreds of antibody interaction studies, across dozens of antibody formats and therapeutic modalities. They are applicable to most antibody discovery and development campaigns.
Recent improvements in antibody discovery and development technologies have allowed an increase in scale – producing more diversity and promising intelligent selection of the best hits. But to achieve scale and efficiency, the assays intended to validate binding, kinetics, epitope and other basic specifications are often run with a generalized set of parameters. As a result, many complex antibody interactions are interpreted through simple binding models, often missing valuable mechanistic insights.
Here, we will break down some of the most overlooked complex binding modalities – how to detect and validate them as well as what impact they might have on your antibody development. We hope that you can learn from these unexpected results, which significantly influence antibody characterization. Please join us to learn from real HDX-MS and SPR case studies and improve the quality and confidence of your antibody characterization data.
Speaker Bios
Marko Jovic, PhD
Rapid Novor
Marko leads our Antibody Kinetics team with over 15 years of experience in antibody optimization and development. In his role as a Product Manager, he is using the power of surface plasmon resonance to realize the full potential of antibodies in the development of the next generation of biologics.
Prior to joining Rapid Novor, Marko held leadership roles in biotech, academia, and governmental organizations ranging from the NIH to Nicoya Lifesciences and the Nebraska Medical Center. He has successfully implemented numerous antibody development projects and trained over 100 researchers in the exciting science of SPR.
Dominic Narang, PhD
Sr. Scientist, HDX-MS
Rapid Novor
Dominic leads the HDX-MS service team at Rapid Novor, bringing ten-plus years of experience in mass spectrometry. He specializes in providing solutions to biotechnology and pharma companies for their drug discovery and development platforms using Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS), a powerful tool for characterizing antibody-antigen interactions.
Prior to joining Rapid Novor, Dominic held positions at prestigious academic and industrial settings, including the University of California – San Diego, York University, and Sanofi Pasteur – Toronto. He has a proven track record of successfully delivering numerous antibody characterization projects using HDX-MS.